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In the clinical management of arthritis, the choice of nonsteroidal anti inﬂammatory drug (NSAID) remains confusing and
controversial. A common practice on the choice of NSAID in clinical management of arthritis is the risk beneﬁt ratio. The main
objective of this review is to addresses the main arguments for the pharmacological and clinical use of COX-2 inhibitors in relation
to nonselective NSAIDs for the clinical management of arthritis. This review concluded that, both NSAIDs and COX-2 inhibitors
are equally eﬀective and are associated with increased risk of GI, renal, and CV, adverse eﬀects. Complete understanding of the
patient’s comorbid conditions and concomitant medications, coupled with precise monitoring during the treatment, may help to
decrease the threat of adverse eﬀects induced by nonselective NSAIDs and selective COX-2 inhibitors.
1.Introduction
Arthritis is a complex disorder that comprises more than
hundred distinct conditions involving damage to the joints
of the body. Many mediators are known to be involved in the
pathophysiology and progression of arthritis. These include
cartilage-degrading enzymes, cytokines, leukotrienes (LTs),
and prostaglandins (PGs). LTs and PGs are produced by the
activity of three enzymes—5-lipoxygenase, cyclooxygenase
(COX)-1 and COX-2—as part of the arachidonic acid
(AA) pathway. PGs have various physiological and patho-
physiological eﬀects. PGs produced by COX-1 isoenzyme
exert house-keeping functions, including gastric mucosal
defense and renal homeostasis, whereas COX-2 synthesizes
detrimental PGs which are responsible for inﬂammation
and pain. The activity of COX-2 leads to production of
a narrower spectrum of PGs, speciﬁcally PGE2 and PGI2.
The vasodilatory properties of these two molecules increase
mucus production and reduce acid and pepsin levels in the
stomach,therebyprotectingtheintegrityofthegastrointesti-
n a l( G I )m u c o s a[ 1–4].
The ultimate goal for arthritis treatment is the modi-
ﬁcation of disease progression, in combination with anti-
inﬂammatory and analgesic eﬃcacy [5–7]. Traditional non-
selective, nonsteroidal anti-inﬂammatory drugs (NSAIDs)
have been widely used to relieve the pain and inﬂammation
due to osteoarthritis and rheumatoid arthritis. These drugs
possess potent anti-inﬂammatory, analgesic, and antipyretic
activity and are among the most widely used drugs world-
wide and represent a mainstay in the treatment of acute
and chronic pain [8]. However, numerous reported adverse
drug reactions, case-control, and postmarketing surveillance
studies have revealed that their use is frequently associated
with a relatively high incidence of adverse reactions in the
GI tract [9–11]. GI toxicity is clinically important because
it has been shown to increase morbidity and mortality rates
in patients, particularly in the elderly, with chronic therapy
[12–18].
Traditional NSAIDs act by inhibiting both COX-1 and
COX-2, thereby blocking the synthesis of PGs. The GI
adverse events of NSAIDs are majorly due to the decrease
in synthesis of the gastroprotective prostaglandins PGE2 and2 ISRN Pharmacology
PGI2,which are mainly produced by COX-1 [1–4, 10]. To
signiﬁcantly reduce the GI toxicity of NSAIDs, associated
with acute and chronic use and to obtain similar or bet-
ter eﬃcacy, pharmaceutical companies conducted intensive
internationalresearchwhichledtothedevelopmentofCOX-
2 inhibitors [19, 20]. Due to the great expectation, these
drugs were rapidly introduced in the market and gained a
remarkable commercial and therapeutic success [19–23].
2. Safety of TraditionalNSAIDs versus
COX-2 Inhibitors
A number of clinical trials have been conducted over
the past 15 years that generally support the favorable GI
side eﬀect proﬁle of COX-2 selective inhibitors. Traditional
nonselective NSAIDs vary in their propensity to cause
serious GI adverse eﬀects. Ibuprofen is associated with
the lowest risk; diclofenac, naproxen, indometacin, and
ketoprofen have intermediate risks [24]. It was reported
that the point prevalence of ulcers in patients on long-term
NSAID treatment is about 20%, and the annual incidence of
serious complications from these ulcers is 1–4% [25].
A recently published systematic review investigated the
relationship between NSAID use and lower GI outcomes.
This study reported an increase in lower GI injury and
clinical events with traditional NSAIDs, which was
consistent across the heterogeneous collection of trials
[26]. Many other systematic reviews and meta-analysis have
demonstrated comparatively better GI safety for celecoxib,
nimesulide, and etodolac in comparison with the traditional
NSAIDs [27–31].
Celecoxib Long-term Arthritis Safety Study (CLASS)
and Vioxx Gastrointestinal Outcomes Research Study
(VIGOR)—large long-term trials—have been conducted in
patients with rheumatoid arthritis and osteoarthritis, both
involving more than 8,000 subjects. These studies demon-
strated that both celecoxib and valdecoxob signiﬁcantly
reduced the risk of major GI side eﬀects compared to tradi-
tional NSAIDs [32, 33]. Similar results were obtained in the
Therapeutic Arthritis Research and Gastrointestinal Event
Trial (TARGET), conducted on 18,325 patients, comparing
lumiracoxibwithtwoNSAIDs,naproxenandibuprofen[34].
Thus ﬁndings of published data reveal that the incidence
of adverse GI eﬀects is signiﬁcantly reduced among patients
taking selective COX-2 inhibitors.
3. Efﬁcacy andSafety of COX-2 Inhibitors
Even though the GI toxicity proﬁle of selective COX-2
inhibitors is better than the traditional NSAIDs, current evi-
dences indicate that selective COX-2 inhibitors have impor-
tant adverse cardiovascular and renal eﬀects. The cardiovas-
cular adverse events of selective COX-2 inhibitors include
increased risk for myocardial infarction, stroke, heart failure,
andhypertension.Thesciencebehindthecardiovascularand
renal adverse events is explained in literatures [35–38].
Rofecoxib’s potential for adverse cardiovascular events
was recognized during the VIGOR trial in which patients
with rheumatoid arthritis were randomized to 50mg of
rofecoxib once a day or 500mg of naproxen twice a day.
This study indicated a fourfold increase in the incidence
of myocardial infarction in the rofecoxib treatment group
compared with the naproxen treatment group [33]. A
recent study has shown that long-term etoricoxib use is
associated with a risk of thrombotic cardiovascular events
comparable with that of diclofenac and with a greater risk
of renovascular adverse events [39]. A meta-analysis of pub-
lished and unpublished tabular data from randomized trials
revealed that selective COX-2 inhibitors are associated with
a moderate increase in the risk of vascular events (relative
risk, 1.42; 95% CI, 1.13 to 1.76), as are high-dose regimens
of ibuprofen and diclofenac, but high-dose naproxen is not
associated with such an excess [40]. High cardiovascular risk
associated with sulphone COX-2 inhibitors such as rofecoxib
and etoricoxib, as observed in recent clinical trials can be
explainedbythedosedependentpro-oxidantactivityofthese
classes of drugs in human plasma samples and isolated low-
density lipoprotein [41, 42].
Several randomized controlled clinical trials in patients
with rheumatoid arthritis or osteoarthritis have demon-
strated that COX-2 inhibitors are no more eﬀective than
traditional NSAIDs or in other words, have similar eﬃcacy
as traditional NSAIDs [27, 43–46].
4. Impact of COX-2 Inhibitorson
Clinical Management of Arthritis
It is a widespread postulation that all NSAIDs, including
COX-2 inhibitors, should be avoided, wherever possible, in
patients with high risk of GI complications. The choice of
NSAID remains confusing and controversial in the clinical
management of arthritis. A common accord on the choice
of drug in clinical management of arthritis is the risk beneﬁt
ratio.
Any patient requiring chronic NSAID treatment for
the management of arthritis may beneﬁt from the COX-
2 therapy. Patients who are at a high risk of GI bleeding,
have a history of intolerance to traditional NSAIDs, or are
not responding to traditional NSAIDs may be appropriate
candidates for treatment with COX-2 selective inhibitors.
These include the elderly, those with documented prior
ulcers, and patients on concomitant steroids. In patients
who are not at a high risk of serious GI events, cost should
be considered as an important factor while considering the
treatment options. Physicians should exercise extra caution
when prescribing COX-2 inhibitors to patients with risk
factors for heart disease. Patients with established ischemic
heart disease, peripheral arterial disease, or cerebrovascular
disease should be switched to traditional NSAIDs and gas-
troprotective agents should be considered in this situation.
COX-2 inhibitors may be preferable in patients taking
low-dose aspirin, since they do not interfere with platelet
inhibition by aspirin
5. Conclusion
Extensive evaluation of the safety and eﬃcacy of NSAIDs
and selective COX-2 inhibitors has revealed that both drugsISRN Pharmacology 3
are equally eﬀective and are associated with increased risk of
G I ,r e n a l ,a n dC V ,a d v e r s ee ﬀects. Physicians have to revise
their indications for both the traditional NSAIDs and the
COX-2 inhibitors in the management of arthritis and to
give considerable attention to the balance of beneﬁts and
risks. Thorough assessment of patient’s comorbid conditions
and concomitant medications, along with precise moni-
toring during therapy, may help to decrease the threat of
toxicity induced by traditional NSAIDs and selective COX-
2 inhibitors.
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